Product Information
ACETAMINOPHEN 325 MG TABLET is a generic product labeled by Aarna USA Inc., priced at $0.0233 per EA under NDC 82568000102. Its NADAC has been published 36 times since Jan 28, 2026.
Strength
325 mg/1
Manufacturer
Aarna USA Inc.NDC
82568000102
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHENApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
5/15/2025
Price Statistics
The NADAC for ACETAMINOPHEN 325 MG TABLET has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 10.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0233 per EA |
|---|---|
| All-time high | $0.0262 (Apr 15, 2026) |
| All-time low | $0.0233 (Sep 23, 2026) |
| 52-week high | $0.0262 |
| 52-week low | $0.0233 |
| Median price | $0.0252 |
| Average price | $0.0252 |
| Largest weekly change | -3.1% (May 20, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aarna USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACETAMINOPHEN 325 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ACETAMINOPHEN 325 MG TABLET, manufactured by Aarna USA Inc., is $0.0233 per EA (NDC 82568000102), effective Sep 30, 2026.
How has the price of ACETAMINOPHEN 325 MG TABLET changed over time?
Over the history we have for it, the NADAC for ACETAMINOPHEN 325 MG TABLET has declined 10.7%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for ACETAMINOPHEN 325 MG TABLET?
Since Jan 28, 2026, the NADAC for ACETAMINOPHEN 325 MG TABLET has ranged from a low of $0.0233 (Sep 23, 2026) to a high of $0.0262 (Apr 15, 2026), with a median of $0.0252 per EA.
Are there cheaper alternatives to ACETAMINOPHEN 325 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACETAMINOPHEN 325 MG TABLET, is $0.0110 per EA — about 53% below ACETAMINOPHEN 325 MG TABLET.
Who manufactures ACETAMINOPHEN 325 MG TABLET?
ACETAMINOPHEN 325 MG TABLET (NDC 82568000102) is labeled by Aarna USA Inc., and CMS classifies it as a generic product.